Related references
Note: Only part of the references are listed.A Walk in Nature: Sesquiterpene Lactones as Multi-Target Agents Involved in Inflammatory Pathways
Adriana Coricello et al.
CURRENT MEDICINAL CHEMISTRY (2020)
Inhibition of JAK/STAT signaling in rheumatologic disorders: The expanding spectrum
Thomas El Jammal et al.
JOINT BONE SPINE (2020)
JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia
Sangeetha Venugopal et al.
BLOOD REVIEWS (2020)
Mediterranean products as promising source of multi-target agents in the treatment of metabolic syndrome
Donatella Bagetta et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Molecular modelling of epitopes recognized by neoplastic B lymphocytes in Chronic Lymphocytic Leukemia
Antonio Lupia et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
Chiara Tarantelli et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases
Arezoo Hosseini et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Peter Richardson et al.
LANCET (2020)
The Physiopathology of T- Cell Acute Lymphoblastic Leukemia: Focus on Molecular Aspects
Bruno Fattizzo et al.
FRONTIERS IN ONCOLOGY (2020)
Mechanism of baricitinib supports artificial intelligence-predicted testing inCOVID-19 patients
Justin Stebbing et al.
EMBO MOLECULAR MEDICINE (2020)
Multi-target drug discovery: An opportunity for novel and repurposed bioactive compounds
Stefano Alcaro et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Design, synthesis, and pharmacological evaluation of 4-or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors
Lei Shu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease
Sameem M. Abedin et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
Yang Cao et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Fragment-Based Discovery of Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity
Bettina Borreschmidt Hansen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Multi-Targeting Bioactive Compounds Extracted from Essential Oils as Kinase Inhibitors
Annalisa Maruca et al.
MOLECULES (2020)
HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19
Francesca Romana Spinelli et al.
SCIENCE IMMUNOLOGY (2020)
The off-label uses profile of tofacitinib in systemic rheumatic diseases
Zichu Zhao et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
The CoV-2 outbreak: how hematologists could help to fight Covid-19
Sara Galimberti et al.
PHARMACOLOGICAL RESEARCH (2020)
Computer-based techniques for lead identification and optimization II: Advanced search methods
Antonio Lupia et al.
PHYSICAL SCIENCES REVIEWS (2020)
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
Emma Guttman-Yassky et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
George E. Fragoulis et al.
RHEUMATOLOGY (2019)
Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis
Amanda Mogul et al.
ANNALS OF PHARMACOTHERAPY (2019)
The impact of binding site waters on the activity/selectivity trade-off of Janus kinase 2 (JAK2) inhibitors
Attila Egyed et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
Structure-based design and synthesis of pyrimidine-4,6-diamine derivatives as Janus kinase 3 inhibitors
Ru-Nan Yu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
Tofacitinib: A Review in Psoriatic Arthritis
Julia Paik et al.
DRUGS (2019)
Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial
David E. Spaner et al.
CANCER MEDICINE (2019)
Editorial: Multi-Target-Directed Ligands (MTDL) as Challenging Research Tools in Drug Discovery: From Design to Pharmacological Evaluation
Stefano Alcaro et al.
FRONTIERS IN CHEMISTRY (2019)
Peficitinib: First Global Approval
Anthony Markham et al.
DRUGS (2019)
Stereoelectronic Effects in Ligand Design: Enantioselective Rhodium-Catalyzed Hydrogenation of Aliphatic Cyclic Tetrasubstituted Enamides and Concise Synthesis of (R)-Tofacitinib
Chengxi Li et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2019)
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan
Tsutomu Takeuchi et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial
Mark C. Genovese et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation
Florian Perner et al.
CELLS (2019)
Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma
Seok Jin Kim et al.
BMC CANCER (2019)
The Mediterranean Diet as source of bioactive compounds with multi-targeting anti-cancer profile
Annalisa Maruca et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Crossroads of Cancer and HIV-1: Pathways to a Cure for HIV
Christina Gavegnano et al.
FRONTIERS IN IMMUNOLOGY (2019)
Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib
Elena Maria Elli et al.
FRONTIERS IN ONCOLOGY (2019)
Novel natural non-nucleoside inhibitors of HIV-1 reverse transcriptase identified by shape- and structure-based virtual screening techniques
Giosue Costa et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine
Raffaella Catalano et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Review about the multi-target profile of resveratrol and its implication in the SGK1 inhibition
Giada Catalogna et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial
Desiree van der Heijde et al.
LANCET (2019)
Ruxolitinib In The Treatment Of Polycythemia Vera: An Update On Health-Related Quality Of Life And Patient-Reported Outcomes
Shashank Cingam et al.
JOURNAL OF BLOOD MEDICINE (2019)
Computer-based techniques for lead identification and optimization I: Basics
Annalisa Maruca et al.
PHYSICAL SCIENCES REVIEWS (2019)
Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy
Vivy Tran et al.
CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY (2019)
Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies
Julian Panes et al.
JOURNAL OF CROHNS & COLITIS (2018)
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases (vol 16, pg 843, 2017)
Daniella M. Schwartz et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Structure-based design and synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amino derivatives as Janus kinase 3 inhibitors
Yuan Yin et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Rational drug design and synthesis of new alpha-Santonin derivatives as potential COX-2 inhibitors
Adriana Coricello et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study
F. Valenzuela et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-serve psoriasis: phase II, randomized, double-blind, placebo-controlled study
G. J. Schmieder et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Putative dual inhibitors of Janus kinase 1 and 3 (JAK1/3): Pharmacophore based hierarchical virtual screening
Haneesh Jasuja et al.
COMPUTATIONAL BIOLOGY AND CHEMISTRY (2018)
A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
Eric Van den Neste et al.
HAEMATOLOGICA (2018)
Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment
Christine Lam et al.
HAEMATOLOGICA (2018)
An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
A. Jabbari et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Drug repurposing in kidney disease
Usha Panchapakesan et al.
KIDNEY INTERNATIONAL (2018)
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
Gerd R. Burmester et al.
LANCET (2018)
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
Daniel J. Wallace et al.
LANCET (2018)
JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial
Katherine R. Tuttle et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
In Silico Identification of Piperidinyl-amine Derivatives as Novel Dual Binders of Oncogene c-myc/c-Kit G-quadruplexes
Roberta Rocca et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
Eric Van den Neste et al.
HAEMATOLOGICA (2018)
Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment
Christine Lam et al.
HAEMATOLOGICA (2018)
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis A Randomized Clinical Trial
John Mascarenhas et al.
JAMA ONCOLOGY (2018)
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
Kim Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
Nikolas von Bubnoff et al.
BMC CANCER (2018)
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial
Desiree van der Heijde et al.
LANCET (2018)
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
Philip Mease et al.
LANCET (2018)
Asymmetric Synthesis of a Key Intermediate for Tofacitinib via a Dynamic Kinetic Resolution-Reductive Amination Protocol
Gerard K. M. Verzijl et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2018)
Ruxolitinib for the Treatment of Essential Thrombocythemia
Arief Gunawan et al.
HEMASPHERE (2018)
A perspective on multi-target drug discovery and design for complex diseases
Rona R. Ramsay et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2018)
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
John O. Mascarenhas et al.
HAEMATOLOGICA (2017)
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
John O. Mascarenhas et al.
HAEMATOLOGICA (2017)
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
Severine Vermeire et al.
LANCET (2017)
Monitoring multiple myeloma by idiotype-specific peptide binders of tumor-derived exosomes
Enrico Iaccino et al.
MOLECULAR CANCER (2017)
Chemoinformatic Database Building and in Silico Hit-Identification of Potential Multi-Targeting Bioactive Compounds Extracted from Mushroom Species
Annalisa Maruca et al.
MOLECULES (2017)
Formal asymmetric synthesis of (+)-tofacitinib
Hao-Chun Liao et al.
TETRAHEDRON-ASYMMETRY (2017)
Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors
Christina Gavegnano et al.
PLOS PATHOGENS (2017)
Tofacitinib: A Review in Rheumatoid Arthritis
Sohita Dhillon
DRUGS (2017)
A Pilot Randomized Trial on Safety and Efficacy of a Novel Topical Combined Inhibitor of Janus Kinase 1/3 and Spleen Tyrosine Kinase for GVHD-Associated Ocular Surface Disease
Ahmad Kheirkhah et al.
CORNEA (2017)
JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
Shubhasree Banerjee et al.
DRUGS (2017)
Discovery of Subtype Selective Janus Kinase (JAK) Inhibitors by Structure-Based Virtual Screening
David Bajusz et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2016)
An Efficient Method for Synthesis of Tofacitinib Citrate
Shuang Zhi et al.
JOURNAL OF HETEROCYCLIC CHEMISTRY (2016)
Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma
Shuqun Yang et al.
ONCOTARGET (2016)
Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors
Vladimir Simov et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Innovation in the pharmaceutical industry: New estimates of R&D costs
Joseph A. DiMasi et al.
JOURNAL OF HEALTH ECONOMICS (2016)
Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients
S. Mimmi et al.
LEUKEMIA (2016)
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2016)
Fragment-Based Discovery of 6-Arylindazole JAK Inhibitors
Andreas Ritzen et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Rationally Repurposing Ruxolitinib (Jakafi®) as a Solid Tumor Therapeutic
Mehrad Tavallai et al.
FRONTIERS IN ONCOLOGY (2016)
Regio- and Enantioselective Synthesis of N-Substituted Pyrazoles by Rhodium-Catalyzed Asymmetric Addition to Allenes
Alexander M. Haydl et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
John J. O'Shea et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis
Greg L. Plosker
DRUGS (2015)
Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia
Carmen Vicente et al.
HAEMATOLOGICA (2015)
Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia
Carmen Vicente et al.
HAEMATOLOGICA (2015)
The molecular regulation of Janus kinase (JAK) activation
Jeffrey J. Babon et al.
BIOCHEMICAL JOURNAL (2014)
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
Silvia Spoerl et al.
BLOOD (2014)
Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
James D. Clark et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
An Improved and Efficient Process for the Preparation of Tofacitinib Citrate
Yogesh S. Patil et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2014)
Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition
Patrick J. Lupardus et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Discovery of novel α-amylase inhibitors using structure-based drug design
Jamil Al-Asri et al.
Journal of Cheminformatics (2014)
Janus kinase inhibitors in autoimmune diseases
John J. O'Shea et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Janus Kinase Inhibition with Tofacitinib: Changing the Face of Inflammatory Bowel Disease Treatment
Lucine Vuitton et al.
CURRENT DRUG TARGETS (2013)
Virtual Screening Strategies in Drug Discovery: A Critical Review
A. Lavecchia et al.
CURRENT MEDICINAL CHEMISTRY (2013)
Tofacitinib: A Review of its Use in Adult Patients with Rheumatoid Arthritis
Lesley J. Scott
DRUGS (2013)
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma
Zhengyan Kan et al.
GENOME RESEARCH (2013)
Asymmetric total synthesis of Tofacitinib
Adolfo Marican et al.
TETRAHEDRON LETTERS (2013)
FDA approves tofacitinib for rheumatoid arthritis
Kate Traynor
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2012)
Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis
Kris Vaddi et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
John J. O'Shea et al.
IMMUNITY (2012)
Evolution of the eukaryotic protein kinases as dynamic molecular switches
Susan S. Taylor et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2012)
CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP
Wei Ju et al.
BLOOD (2011)
The Use of Structural Biology in Janus Kinase Targeted Drug Discovery
Nilda L. Alicea-Velazquez et al.
CURRENT DRUG TARGETS (2011)
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
Alfonso Quintas-Cardama et al.
BLOOD (2010)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains
Neal K. Williams et al.
JOURNAL OF MOLECULAR BIOLOGY (2009)
Enantioselective Synthesis of Janus Kinase Inhibitor INCB018424 via an Organocatalytic Aza-Michael Reaction
Qiyan Lin et al.
ORGANIC LETTERS (2009)
Mild and Efficient DBU-Catalyzed Amidation of Cyanoacetates
Kristin E. Price et al.
ORGANIC LETTERS (2009)
Intracellular signal pathways: Potential for therapies
Melissa Mavers et al.
Current Rheumatology Reports (2009)
Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges
Laura L. Rokosz et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2008)
Hematopoietic cytokine receptor signaling
S. J. Baker et al.
ONCOGENE (2007)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Investigation of practical routes for the kilogram-scale production of cis-3-methylamino-4-methylpiperidines
WL Cai et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2005)
The many roles of computation in drug discovery
WL Jorgensen
SCIENCE (2004)
The JAK/STAT signaling pathway
JS Rawlings et al.
JOURNAL OF CELL SCIENCE (2004)
Genome-wide analysis of STAT target genes - Elucidating the mechanism of STAT-mediated oncogenesis
JV Alvarez et al.
CANCER BIOLOGY & THERAPY (2004)
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
PS Changelian et al.
SCIENCE (2003)
Characterization and analysis of the proximal Janus kinase 3 promoter
M Aringer et al.
JOURNAL OF IMMUNOLOGY (2003)
Development of a scaleable route for the production of cis-N-benzyl-3-methylamino-4-methylpiperidine
DHB Ripin et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2003)
Cytokines and their role in lymphoid development, differentiation and homeostasis
Sigrun R. Hofmann et al.
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY (2002)
Signaling through the JAK/STAT pathway, recent advances and future challenges
T Kisseleva et al.
GENE (2002)
Share Paper
